Report Thumbnail
Product Code IW091400945HM4
Published Date 2022/3/14
English163 PagesAsia Pacific

ASIA-PACIFIC VETERINARY VACCINES MARKET FORECAST 2022-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code IW091400945HM4◆The Mar 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2022/3/14
English 163 PagesAsia Pacific

ASIA-PACIFIC VETERINARY VACCINES MARKET FORECAST 2022-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

KEY FINDINGS The Asia-Pacific veterinary vaccines market is estimated to register a CAGR of 8.69% during the forecast period, 2022-2030. The growing prioritization of veterinary vaccines by international and regional players in Asia-Pacific with regard to R&D facilities, manufacturing facilities, and investments is a key growth driver. MARKET INSIGHTS Vietnam, China, Australia & New Zealand, Thailand, Indonesia, South Korea, India, Japan, and Rest of Asia-Pacific are assessed for the growth analysis of the Asia-Pacific veterinary vaccines market. In Japan, as per the annual survey by Japan Pet Food Association (JFPA), it had around 18.13 million domesticated cats and dogs. Also, there is a rising incidence of pets suffering from lifestyle-related illnesses associated with old age and obesity, overnutrition, and indoor habitation. These include bladder & urinary tract disease, heart disease, arthritis, spine disease, high blood pressure, chronic kidney disease, etc. Further, in countries like India, with the voluminous presence of animal life, it is necessary to preserve it for sustenance since animal husbandry is a major source of economic growth. For instance, India has a livestock population of 535.78 million and poultry of 851.81 million. Additionally, the country has several domestic players actively engaged in veterinary vaccine selling and manufacturing. Also, the government initiatives have rendered the country a lucrative market regarding business opportunities for international players. Australia has around 30.4 million pets that include birds, fishes, cats, dogs, etc. Accordingly, the government has initiated plans like AUSVETPLAN and AQUAVETPLAN to enhance the focus on animal health. These schemes entail animal welfare, emergency animal disease preparedness, disease control, etc. Such factors drive market growth in these countries. COMPETITIVE INSIGHTS Some of the key companies in the market include Merck Animal Health, Hipra, Indian Immunologicals Limited, Hester Biosciences Ltd, etc. Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents

  • 1 RESEARCH SCOPE & METHODOLOGY

    • 1.1 STUDY OBJECTIVES
    • 1.2 SCOPE OF STUDY
    • 1.3 METHODOLOGY
    • 1.4 ASSUMPTIONS & LIMITATIONS
  • 2 EXECUTIVE SUMMARY

    • 2.1 MARKET SIZE & ESTIMATES
    • 2.2 MARKET OVERVIEW
  • 3 MARKET DYNAMICS

    • 3.1 KEY DRIVERS
      • 3.1.1 RESEARCH & DEVELOPMENT OF ADVANCED VACCINES
      • 3.1.2 NEED OF VACCINE DUE TO RISING ANIMAL POPULATION AND DISEASES
      • 3.1.3 VACCINATION DRIVES BY GOVERNMENT AGENCIES
    • 3.2 KEY RESTRAINTS
      • 3.2.1 RULES & REGULATIONS FOR THE USE OF VACCINE
      • 3.2.2 LACK OF AWARENESS AMONG FARMERS AND REQUIREMENT OF SKILLED VETERINARIANS
  • 4 KEY ANALYTICS

    • 4.1 IMPACT OF COVID-19 ON VETERINARY VACCINES MARKET
    • 4.2 KEY MARKET TRENDS
    • 4.3 PORTER’S FIVE FORCES ANALYSIS
      • 4.3.1 BUYERS POWER
      • 4.3.2 SUPPLIERS POWER
      • 4.3.3 SUBSTITUTION
      • 4.3.4 NEW ENTRANTS
      • 4.3.5 INDUSTRY RIVALRY
    • 4.4 VALUE CHAIN ANALYSIS
    • 4.5 KEY BUYING CRITERIA
    • 4.6 REGULATORY FRAMEWORK
  • 5 MARKET BY ANIMAL TYPE

    • 5.1 LIVESTOCK ANIMAL
      • 5.1.1 CATTLE
      • 5.1.2 PIGS
      • 5.1.3 POULTRY
      • 5.1.4 SHEEP
      • 5.1.5 OTHER LIVESTOCK ANIMALS
    • 5.2 COMPANION ANIMAL
      • 5.2.1 CANINE
      • 5.2.2 FELINE
      • 5.2.3 EQUINE
    • 5.3 AQUACULTURE
  • 6 MARKET BY PRODUCT TYPE

    • 6.1 ATTENUATED VACCINES
    • 6.2 INACTIVATED VACCINES
    • 6.3 TOXOID VACCINES
    • 6.4 CONJUGATE VACCINES
    • 6.5 DNA VACCINES
    • 6.6 RECOMBINANT VACCINES
    • 6.7 SUBUNIT VACCINES
  • 7 MARKET BY DISEASE TYPE

    • 7.1 CANINE DISEASE
    • 7.2 PORCINE DISEASE
    • 7.3 BOVINE DISEASE
    • 7.4 POULTRY DISEASE
    • 7.5 AQUACULTURE DISEASE
    • 7.6 OTHER DISEASES
  • 8 GEOGRAPHICAL ANALYSIS

    • 8.1 ASIA-PACIFIC
      • 8.1.1 MARKET SIZE & ESTIMATES
      • 8.1.2 KEY GROWTH ENABLERS
      • 8.1.3 KEY CHALLENGES
      • 8.1.4 KEY PLAYERS
      • 8.1.5 COUNTRY ANALYSIS
        • 8.1.5.1 CHINA
        • 8.1.5.2 JAPAN
        • 8.1.5.3 INDIA
        • 8.1.5.4 SOUTH KOREA
        • 8.1.5.5 INDONESIA
        • 8.1.5.6 THAILAND
        • 8.1.5.7 VIETNAM
        • 8.1.5.8 AUSTRALIA & NEW ZEALAND
        • 8.1.5.9 REST OF ASIA-PACIFIC
  • 9 COMPETITIVE LANDSCAPE

    • 9.1 KEY STRATEGIC DEVELOPMENTS
      • 9.1.1 MERGERS & ACQUISITIONS
      • 9.1.2 PRODUCT LAUNCHES & DEVELOPMENTS
      • 9.1.3 PARTNERSHIPS & AGREEMENTS
      • 9.1.4 BUSINESS EXPANSIONS & DIVESTITURES
    • 9.2 COMPANY PROFILES
      • 9.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 9.2.2 BRILLIANT BIO PHARMA
      • 9.2.3 CEVA SANTE ANIMALE
      • 9.2.4 ELANCO ANIMAL HEALTH
      • 9.2.5 HESTER BIOSCIENCES LTD
      • 9.2.6 HIPRA
      • 9.2.7 INDIAN IMMUNOLOGICALS LIMITED
      • 9.2.8 MERCK ANIMAL HEALTH
      • 9.2.9 PHIBRO ANIMAL HEALTH
      • 9.2.10 VAXXINOVA GMBH
      • 9.2.11 VIRBAC SA
      • 9.2.12 ZOETIS
USD 1,600 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.